| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 7, Issue 8 1031-1038, Copyright © 1996 by American Association of Cancer Research
ARTICLES |
FE Jones, DJ Jerry, BC Guarino, GC Andrews and DF Stern
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520-8023, USA.
Mammary gland development and differentiation is mediated through the combined activities of systemic hormones and locally synthesized growth factors. To determine the in vivo response of mammary epithelium to heregulin (HRG), we implanted Elvax pellets containing HRG alpha or HRG beta within the mammary glands of prepubescent female mice in the presence or absence of exogenous estradiol and progesterone (E/ P). Mice treated in the same way with transforming growth factor alpha (TGF-alpha) were included as a positive control. Each growth factor treatment induced epithelial ductal branching in the presence or absence of E/P. In the absence of E/P, HRG beta did not effect terminal end bud formation, mammary epitheilum branching, or ductal migration. In contrast, TGF-alpha and HRG alpha induced ductal branching and HRG alpha induced ductal migration in the absence of E/P. The overall mammary response to growth factors was potentiated by the concomitant presence of E/P. In every case, the in vivo mammary epithelial responses to HRG alpha were more robust than TGF-alpha. Limited lobuloalveolar development was also observed in growth factor-treated mammary glands when E/P was present. Histological examination of growth factor-induced lobuloalveoli revealed secretory products within the lumen of HRG alpha and HRG beta lobuloalveoli. TGF-alpha-induced lobuloalveoli lacked similar secretory products.
This article has been cited by other articles:
 |
|
 |
|
  R. S. Muraoka-Cook, M. Sandahl, D. Hunter, L. Miraglia, and H. S. Earp III Prolactin and ErbB4/HER4 Signaling Interact via Janus Kinase 2 to Induce Mammary Epithelial Cell Gene Expression Differentiation Mol. Endocrinol., October 1, 2008; 22(10): 2307 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Muraoka-Cook, M. Sandahl, C. Husted, D. Hunter, L. Miraglia, S.-m. Feng, K. Elenius, and H. S. Earp III The Intracellular Domain of ErbB4 Induces Differentiation of Mammary Epithelial Cells Mol. Biol. Cell, September 1, 2006; 17(9): 4118 - 4129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Howard, H. Panchal, A. McCarthy, and A. Ashworth Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification Genes & Dev., September 1, 2005; 19(17): 2078 - 2090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Barnes, F. Li, A. H. Talukder, and R. Kumar Growth Factor Regulation of a 26S Proteasomal Subunit in Breast Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2868 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Jackson-Fisher, G. Bellinger, R. Ramabhadran, J. K. Morris, K.-F. Lee, and D. F. Stern ErbB2 is required for ductal morphogenesis of the mammary gland PNAS, December 7, 2004; 101(49): 17138 - 17143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Long, K.-U. Wagner, K. C. K. Lloyd, N. Binart, J. M. Shillingford, L. Hennighausen, and F. E. Jones Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5 Development, November 1, 2003; 130(21): 5257 - 5268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Dolce, A. Vakani, L. Archer, J.A. Morris-Wiman, and L.S. Holliday Effects of Echistatin and an RGD Peptide on Orthodontic Tooth Movement J. Dent. Res., September 1, 2003; 82(9): 682 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tidcombe, A. Jackson-Fisher, K. Mathers, D. F. Stern, M. Gassmann, and J. P. Golding Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality PNAS, July 8, 2003; 100(14): 8281 - 8286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-A. Wang, R. K. Vadlamudi, R. Bagheri-Yarmand, I. Beuvink, N. E. Hynes, and R. Kumar Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands J. Cell Biol., May 12, 2003; 161(3): 583 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Penington, I. Bryant, and D. J. Riese II Constitutively Active ErbB4 and ErbB2 Mutants Exhibit Distinct Biological Activities Cell Growth Differ., June 1, 2002; 13(6): 247 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. O'Shea, K. Johnson, R. Clark, M. X. Sliwkowski, and S. L. Erickson Effects of in Vivo Heregulin {beta}1 Treatment in Wild-Type and ErbB Gene-Targeted Mice Depend on Receptor Levels and Pregnancy Am. J. Pathol., May 1, 2001; 158(5): 1871 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. R. Gilmour, K. G. Macleod, A. McCaig, W. J. Gullick, J. F. Smyth, and S. P. Langdon Expression of erbB-4/HER-4 Growth Factor Receptor Isoforms in Ovarian Cancer Cancer Res., March 1, 2001; 61(5): 2169 - 2176. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. K. Vadlamudi, R.-A. Wang, A. H. Talukder, L. Adam, R. Johnson, and R. Kumar Evidence of Rab3A Expression, Regulation of Vesicle Trafficking, and Cellular Secretion in Response to Heregulin in Mammary Epithelial Cells Mol. Cell. Biol., December 1, 2000; 20(23): 9092 - 9101. [Abstract] [Full Text]
|
|
|
|
|
|
R. Srinivasan, C. E. Gillett, D. M. Barnes, and W. J. Gullick Nuclear Expression of the c-erbB-4/HER-4 Growth Factor Receptor in Invasive Breast Cancers Cancer Res., March 1, 2000; 60(6): 1483 - 1487. [Abstract] [Full Text]
|
|
|
|
|
|
K. S.R. Spencer, D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by ErbB Family Receptor Tyrosine Kinases J. Cell Biol., January 24, 2000; 148(2): 385 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-F. Le, A. McWatters, J. Wiener, J.-Y. Wu, G. B. Mills, and R. C. Bast Jr. Anti-HER2 Antibody and Heregulin Suppress Growth of HER2-Overexpressing Human Breast Cancer Cells through Different Mechanisms Clin. Cancer Res., January 1, 2000; 6(1): 260 - 270. [Abstract] [Full Text]
|
|
|
|
|
|
F. E. Jones, T. Welte, X.-Y. Fu, and D. F. Stern ErbB4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation J. Cell Biol., October 4, 1999; 147(1): 77 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vadlamudi, L. Adam, B. Tseng, L. Costa, and R. Kumar Transcriptional Up-Regulation of Paxillin Expression by Heregulin in Human Breast Cancer Cells Cancer Res., June 1, 1999; 59(12): 2843 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hoeben, J. V. Swinnen, W. Heyns, and G. Verhoeven Heregulins or Neu Differentiation Factors and the Interactions between Peritubular Myoid Cells and Sertoli Cells Endocrinology, May 1, 1999; 140(5): 2216 - 2223. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y.-C. Chou, R. C. Guzman, S. M. Swanson, J. Yang, H. M. Lui, V. Wu, and S. Nandi Induction of mammary carcinomas by N-methyl-N-nitrosourea in ovariectomized rats treated with epidermal growth factor Carcinogenesis, April 1, 1999; 20(4): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Luetteke, T. Qiu, S. Fenton, K. Troyer, R. Riedel, A Chang, and D. Lee Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development Development, January 6, 1999; 126(12): 2739 - 2750. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Neve, C. Chang, G. K. Scott, A. Wong, R. R. Friis, N. E. Hynes, and C. C. Benz The epithelium-specific Ets transcription factor ESX is associated with mammary gland development and involution FASEB J, November 1, 1998; 12(14): 1541 - 1550. [Abstract] [Full Text]
|
|
|
|
|
|
A. Chausovsky, I. Tsarfaty, Z. Kam, Y. Yarden, B. Geiger, and A. D. Bershadsky Morphogenetic Effects of Neuregulin (Neu Differentiation Factor) in Cultured Epithelial Cells Mol. Biol. Cell, November 1, 1998; 9(11): 3195 - 3209. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Adam, R. Vadlamudi, S. B. Kondapaka, J. Chernoff, J. Mendelsohn, and R. Kumar Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase J. Biol. Chem., October 23, 1998; 273(43): 28238 - 28246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Riese II, T. Komurasaki, G. D. Plowman, and D. F. Stern Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2 J. Biol. Chem., May 1, 1998; 273(18): 11288 - 11294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Humphreys, J. Lydon, B. W. O’Malley, and J. M. Rosen Mammary Gland Development Is Mediated by Both Stromal and Epithelial Progesterone Receptors Mol. Endocrinol., June 1, 1997; 11(6): 801 - 811. [Abstract] [Full Text]
|
|
|
|
|
|
C. Sweeney, D. Fambrough, C. Huard, A. J. Diamonti, E. S. Lander, L. C. Cantley, and K. L. Carraway III Growth Factor-specific Signaling Pathway Stimulation and Gene Expression Mediated by ErbB Receptors J. Biol. Chem., June 15, 2001; 276(25): 22685 - 22698. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
